Base de dados : MEDLINE
Pesquisa : I01.409.418.750.600.650.496.435 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 MEDLINE  
              next record last record
para imprimir
PubMed Central Texto completo
Texto completo
[Au] Autor:McKee AC; Cairns NJ; Dickson DW; Folkerth RD; Keene CD; Litvan I; Perl DP; Stein TD; Vonsattel JP; Stewart W; Tripodis Y; Crary JF; Bieniek KF; Dams-O'Connor K; Alvarez VE; Gordon WA; TBI/CTE group
[Ad] Endereço:Department of Neurology, Boston University School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA.
[Ti] Título:The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy.
[So] Source:Acta Neuropathol;131(1):75-86, 2016 Jan.
[Is] ISSN:1432-0533
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chronic traumatic encephalopathy (CTE) is a neurodegeneration characterized by the abnormal accumulation of hyperphosphorylated tau protein within the brain. Like many other neurodegenerative conditions, at present, CTE can only be definitively diagnosed by post-mortem examination of brain tissue. As the first part of a series of consensus panels funded by the NINDS/NIBIB to define the neuropathological criteria for CTE, preliminary neuropathological criteria were used by 7 neuropathologists to blindly evaluate 25 cases of various tauopathies, including CTE, Alzheimer's disease, progressive supranuclear palsy, argyrophilic grain disease, corticobasal degeneration, primary age-related tauopathy, and parkinsonism dementia complex of Guam. The results demonstrated that there was good agreement among the neuropathologists who reviewed the cases (Cohen's kappa, 0.67) and even better agreement between reviewers and the diagnosis of CTE (Cohen's kappa, 0.78). Based on these results, the panel defined the pathognomonic lesion of CTE as an accumulation of abnormal hyperphosphorylated tau (p-tau) in neurons and astroglia distributed around small blood vessels at the depths of cortical sulci and in an irregular pattern. The group also defined supportive but non-specific p-tau-immunoreactive features of CTE as: pretangles and NFTs affecting superficial layers (layers II-III) of cerebral cortex; pretangles, NFTs or extracellular tangles in CA2 and pretangles and proximal dendritic swellings in CA4 of the hippocampus; neuronal and astrocytic aggregates in subcortical nuclei; thorn-shaped astrocytes at the glial limitans of the subpial and periventricular regions; and large grain-like and dot-like structures. Supportive non-p-tau pathologies include TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and amygdala. The panel also recommended a minimum blocking and staining scheme for pathological evaluation and made recommendations for future study. This study provides the first step towards the development of validated neuropathological criteria for CTE and will pave the way towards future clinical and mechanistic studies.
[Mh] Termos MeSH primário: Lesão Encefálica Crônica/diagnóstico
Emaranhados Neurofibrilares/patologia
[Mh] Termos MeSH secundário: Doença de Alzheimer/patologia
Lesão Encefálica Crônica/fisiopatologia
Seres Humanos
National Institute of Biomedical Imaging and Bioengineering (U.S.)
National Institute of Neurological Disorders and Stroke (USA)
Estados Unidos
Proteínas tau/metabolismo
[Nm] Nome de substância:
0 (tau Proteins)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151216
[St] Status:MEDLINE
[do] DOI:10.1007/s00401-015-1515-z

  2 / 2 MEDLINE  
              first record previous record
para imprimir
Texto completo
[Au] Autor:Kelly KA; Hollingsworth MA; Brand RE; Liu CH; Singh VK; Srivastava S; Wasan AD; Yadav D; Andersen DK
[Ad] Endereço:From the *Department of Biomedical Engineering, University of Virginia, Charlottesville, VA; †Eppley Cancer Institute, University of Nebraska School of Medicine, Omaha, NE; ‡Division of Gastroenterology, Hepatology and Nutrition, Departments of Medicine and Anesthesiology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA; §Office of Cancer Nanotechnology Research and the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; ∥Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ¶Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; and #Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
[Ti] Título:Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop.
[So] Source:Pancreas;44(8):1185-94, 2015 Nov.
[Is] ISSN:1536-4828
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Biomedical Imaging and Bioengineering focused on research gaps and opportunities in the development of new biomarkers of pancreatic disease. The session was held on July 22, 2015, and structured into 6 sessions: 1) Introduction and Overview; 2) Keynote Address; 3) New Approaches to the Diagnosis of Chronic Pancreatitis; 4) Biomarkers of Pain and Inflammation; 5) New Approaches to the Detection of Pancreatic Cancer; and 6) Shed Exosomes, Shed Cells, and Shed Proteins. Recent advances in the fields of pancreatic imaging, functional markers of pancreatic disease, proteomics, molecular and cellular imaging, and detection of circulating cancer cells and exosomes were reviewed. Knowledge gaps and research needs were highlighted. The development of new methods for the noninvasive determination of pancreatic pathology; the use of cellular markers of pancreatic function, inflammation, pain, and malignancy; and the refinement of methods to identify cells and cellular constituents of pancreatic cancer were discussed. The further refinement of sophisticated technical methods and the need for clinical studies to validate these new approaches in large-scale studies of patients at risk for the development of pancreatic disease were repeatedly emphasized.
[Mh] Termos MeSH primário: Bioengenharia/métodos
Diagnóstico por Imagem/métodos
[Mh] Termos MeSH secundário: Bioengenharia/tendências
Diagnóstico por Imagem/tendências
Seres Humanos
National Institute of Biomedical Imaging and Bioengineering (U.S.)
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/terapia
Pancreatite Crônica/diagnóstico
Pancreatite Crônica/terapia
Estados Unidos
[Pt] Tipo de publicação:CONGRESSES
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151015
[St] Status:MEDLINE
[do] DOI:10.1097/MPA.0000000000000552

página 1 de 1

Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde